Senior Director of Fibrosis, Hepatic and Pulmonary Research

Dr. Leeming joined Nordic Bioscience in 2004 and assumed the position as Director of Fibrosis in 2010. She has been promoted to Senior Director in 2024. Her focus is on the development of serologically assessed markers to evaluate the extracellular matrix remodeling in patients with pulmonary or hepatic fibrosis for diagnosis or pharmacodynamic evaluation. Dr. Leeming is a principle inventor of PRO-C3 assay, a fibrogenesis marker used in multiple clinical trial studies. She has 280+ peer-reviewed publications.

H-index: 61. I10-index: 174. Citations: 11825 as of March 2024.

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.